Pharmacology: Pharmacodynamics: This product combines the potent topical antibacterial action of fusidic acid with the anti-inflammatory and antipruritic effects of betamethasone. Betamethasone is a topical steroid with rapid effect in inflammatory dermatoses. Even refractory conditions can often be treated successfully. When applied topically, fusidic acid is effective against Staphylococci, Streptococci, Corynebacteria, Neisseria and certain Clostridia and Bacteroides.
Pharmacokinetics: Fusidic Acid and its salts are widely distributed into tissues and body fluids, including bone, pus, and synovial fluid; it penetrates cerebral abscesses but does not enter cerebrospinal fluid in appreciable amounts. It has been found in the foetal circulation and in breast milk. About 95% or more of Fusidic Acid in the circulation is bound to plasma protein. Fusidic Acid is excreted in the bile, almost entirely as metabolites some of which have weak antimicrobial activity. About 2% appears unchanged in the faeces. Little is excreted in the urine or removed by haemodialysis. Betamethasone Dipropionate have anti-inflammatory, anti-pruritic and vasoconstrictive actions, when administered topically, particularly under occlusive dressing or when the skin is broken, sufficient corticosteroid may be absorbed to give systemic effects. Corticosteroids are extensively bound to the plasma proteins. Only unbound corticosteroid has pharmacological effects or is metabolised. They are metabolised mainly in the liver, also in the kidney, and are excreted in the urine.